Brian Hubbard
Direktor/Vorstandsmitglied bei Mediar Therapeutics, Inc.
Ursprung des Netzwerks ersten Grades von Brian Hubbard
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA.
9
| Holding Company | Biotechnology | 9 |
Elgia Therapeutics, Inc.
Elgia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elgia Therapeutics, Inc. engages in the provision of pharmaceutical services. The company was founded in 2019 and is headquartered in San Diego, CA.
3
| Private Company | Pharmaceuticals: Major | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Brian Hubbard
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
AGIOS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
IXICO PLC | Miscellaneous Commercial Services | Director/Board Member | |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Biotechnology | Chief Executive Officer | |
Brown University | College/University | Undergraduate Degree | |
Ampersand Management LLC
Ampersand Management LLC Investment ManagersFinance Ampersand Management LLC (Ampersand Management) is a private equity firm founded in 1988 by Richard A. Charpie. The firm is headquartered in Wellesley, Massachusetts. | Investment Managers | Private Equity Investor | |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Private Equity Investor | |
Syracuse University | College/University | Undergraduate Degree | |
The Johns Hopkins University | College/University | Graduate Degree | |
The Pennsylvania State University | College/University | Undergraduate Degree | |
University of Illinois | College/University | Doctorate Degree Graduate Degree | |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Investment Managers | Private Equity Investor | |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Private Equity Investor | |
Robert Wood Johnson Medical School | College/University | Doctorate Degree | |
Chimeric Therapies, Inc. | Corporate Officer/Principal | ||
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Investment Managers | Private Equity Investor | |
Topivert Pharma Ltd.
Topivert Pharma Ltd. Pharmaceuticals: MajorHealth Technology Topivert Pharma Ltd. is a British pharmaceutical company founded in 2011. The private company develops non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal. | Pharmaceuticals: Major | Director/Board Member | |
Rutgers Business School | College/University | Masters Business Admin | |
Georgetown University School of Medicine | College/University | Doctorate Degree | |
Lundbeckfonden Emerge
Lundbeckfonden Emerge Investment ManagersFinance Lundbeckfonden Emerge (Emerge) is a venture capital firm wholly-owned by the Lundbeck Foundation. The firm was established in 2012 and is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor | |
Imperial College Business School | College/University | Masters Business Admin | |
Northern Biologics, Inc.
Northern Biologics, Inc. Hospital/Nursing ManagementHealth Services Northern Biologics Inc. operates as an early-stage biologics company. It develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company was founded by Jason Moffat, Rob Rottapel, Benjamin G. Neel, Sachdev Sidhu, Brad Wouters, and Stefan Larson in June 2014 and is headquartered in Toronto, Canada. | Hospital/Nursing Management | Corporate Officer/Principal | |
Kesios Therapeutics Ltd.
Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member | |
Mironid Ltd.
Mironid Ltd. Pharmaceuticals: MajorHealth Technology Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
Abcuro, Inc.
Abcuro, Inc. Miscellaneous Commercial ServicesCommercial Services Abcuro, Inc. develops bio-therapeutics for the treatment of autoimmunity and cancer. the company was founded in 2015 and is headquartered in Newton, MA. | Miscellaneous Commercial Services | Chief Executive Officer | |
Jecure Therapeutics, Inc.
Jecure Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jecure Therapeutics, Inc. provides therapeutic services for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company was founded by Ariel Feldstein in 2015 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Medical Specialties | Director/Board Member | |
Magnolia Neurosciences Corp.
Magnolia Neurosciences Corp. BiotechnologyHealth Technology Magnolia Neurosciences Corp. operates as a drug discovery and development company. The firm focuses on the creation of a novel class of neuroprotective medicines. The company was founded in 2018 and is headquartered in Seattle, WA. | Biotechnology | Director/Board Member | |
TSCAN THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith. | Biotechnology | Director/Board Member Director/Board Member | |
Capstan Therapeutics, Inc.
Capstan Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capstan Therapeutics, Inc. is a biotechnology company based in San Diego, CA. Capstan Therapeutics aims to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The company's platform technology, TLNPs, is designed to deliver payloads and gene editing tools to reprogram specific cell types in vivo. This technology has the potential to generate transformative therapies for various disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. Capstan Therapeutics, Inc. was founded in 2022 by Haig Aghajanian. Laura K. Shawver has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Comet Therapeutics, Inc.
Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Financial Conglomerates | Director/Board Member | |
CINCOR PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
Renovacor Holdings, Inc.
Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
Vaderis Therapeutics AG
Vaderis Therapeutics AG BiotechnologyHealth Technology Vaderis Therapeutics AG is a clinical stage biotech company based in Basel, Switzerland. The Swiss company aims to develop medicinal treatments for rare and orphan diseases associated with vascular malformations. The company focuses on developing a medicine for the treatment of HHT and other diseases associated with vascular malformations. HHT is a rare disease that causes vascular overgrowth due to genetic mutations, and there are no drugs approved anywhere in the world that specifically treat it. The company was founded in 2019 by Nicholas Benedict, Pierre Saint-Mezard, and Damien Picard, and Nicholas Benedict has been the CEO since incorporation. Vaderis raised a series a financing from Medicxi and acquired a portfolio of allosteric Akt inhibitors from Almac Discovery Ltd. | Biotechnology | Director/Board Member | |
ENLIVEN THERAPEUTICS, INC. | Biotechnology | Director/Board Member |
Statistik
International
Vereinigte Staaten | 29 |
Vereinigtes Königreich | 11 |
Frankreich | 4 |
Schweiz | 3 |
Niederlande | 2 |
Sektoral
Health Technology | 23 |
Consumer Services | 10 |
Finance | 8 |
Commercial Services | 6 |
Technology Services | 2 |
Operativ
Director/Board Member | 62 |
Chairman | 20 |
Corporate Officer/Principal | 17 |
Chief Executive Officer | 14 |
Private Equity Investor | 11 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Peter D. Parker | 34 |
Maina Bhaman | 26 |
Simon Sturge | 20 |
Michael Baran | 14 |
Rahul Ballal | 13 |
Andreas Jurgeit | 8 |
David de Graaf | 6 |
Nandita Shangari | 5 |
Stacie Canan | 4 |
Ariel Feldstein | 2 |
Paul Yaworsky | 1 |
Alan Saltiel | 1 |
- Börse
- Insiders
- Brian Hubbard
- Unternehmensverbindungen